This study tests a new drug called elismetrep for treating migraines, a type of headache. The study is a randomized, double-blind, placebo-controlled trial, meaning some people will get the actual drug, and others will get a placebo (a fake pill) without knowing which one they are getting. The goal is to see if elismetrep is safe and effective for people with moderate or severe migraines. Participants must be between 18 and 70 years old and have had migraines for over a year.

• Study lasts for several months and requires regular visits to the study center.
• Participants must agree to use a smartphone app to track their migraines.
• Those participating must not be pregnant or planning to become pregnant during the study.

Participants will be carefully selected based on their health history to ensure safety. This includes not having certain medical conditions like heart disease or recent surgeries. People with certain types of migraines or on specific medications may not be eligible. Compensation may be provided for time and travel, and all participants will give informed consent to join. Only those who fit the criteria should consider participating.